Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EPS (Weighted Average and Diluted)Shares Outstanding (Weighted Average)
Others
Ratios

China SXT Pharmaceuticals (SXTC) Restructuring Costs: 2020-2023

  • China SXT Pharmaceuticals' Restructuring Costs was N/A to $164.1 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $164.1 billion, marking a year-over-year change of. This contributed to the annual value of $379,997 for FY2025, which is 26.85% up from last year.
  • As of Q3 2023, China SXT Pharmaceuticals' Restructuring Costs stood at $164.1 billion, which was up 71,141,251.50% from $230,642 recorded in Q1 2023.
  • In the past 5 years, China SXT Pharmaceuticals' Restructuring Costs ranged from a high of $296.0 billion in Q3 2020 and a low of $180,370 during Q1 2021.
  • Its 2-year average for Restructuring Costs is $41.0 billion, with a median of $212,742 in 2021.
  • Data for China SXT Pharmaceuticals' Restructuring Costs shows a maximum YoY slumped of 100.00% (in 2021) over the last 5 years.
  • Over the past 3 years, China SXT Pharmaceuticals' Restructuring Costs (Quarterly) stood at $296.0 billion in 2020, then crashed by 100.00% to $194,841 in 2021, then reached $164.1 billion in 2023.
  • Its last three reported values are $164.1 billion in Q3 2023, $230,642 for Q1 2023, and $194,841 during Q3 2021.